Aurobindo Pharma

Last updated

Aurobindo Pharma Limited
Company type Public
NSE:  AUROPHARMA
BSE:  524804
Industry Pharmaceuticals
Founded1986
FoundersV. Ramprasad Reddy [1]
K. Nityananda Reddy [1]
Headquarters Hyderabad, Telangana, India
Products
RevenueIncrease2.svg₹29,002 crore (US$3.5 billion) (FY24) [3]
Increase2.svg₹5,843 crore (US$700 million) (FY24) [3]
Increase2.svg₹3,173 crore (US$380 million) (FY24) [3]
Total assets Increase2.svg₹28,926 crore (US$3.5 billion) (2020) [4]
Total equity Increase2.svg₹16,751 crore (US$2.0 billion) (2020) [4]
Number of employees
23,000 [5]  (2020)
Website www.aurobindo.com

Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. [6] The company markets these products in over 125 countries. [6] Its marketing partners include AstraZeneca [7] and Pfizer. [8]

Contents

History

Aurobindo Pharma clindamycin capsules Clindamycin.jpg
Aurobindo Pharma clindamycin capsules

The company commenced operations in 1988–89 with a single unit manufacturing semi-synthetic penicillin (SSP) in Puducherry. [9] Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. Aurobindo Pharma also has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.

Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues. [6] Aurobindo exports to over 125 countries with more than 70% of its revenues derived out of international operations.

In 2014, Aurobindo purchased the generic operations of Actavis in 7 Western European countries for $41 million. [10] [11]

Business expansion

Aurobindo Pharma plans to expand its product portfolio with high-value products in oncology, hormones, biosimilars and novel drug delivery solutions like depot injections, inhalers, patches and films. It has also set its sights on geographic expansion in new territories like Poland, Italy, Spain, Czech Republic, Portugal and France, as the generic drug market in these countries is relatively small. [12]

In 2017, Aurobindo Pharma inked a pact to acquire Portugal’s Generis Farmaceutica SA from Magnum Capital Partners for a consideration of €135 million. [13] It also acquired four biosimilar products from Swiss firm TL Biopharmaceutical AG. [14]

Aurobindo Pharma Ltd. signed a definitive agreement to purchase the Apotex businesses in Poland, the Czech Republic, the Netherlands, Spain and Belgium. The agreement is conditional on the receipt of competition clearances for the transaction by the Dutch and Polish authorities. As part of the proposed sale, Apotex will enter into a transitional manufacturing and supply arrangement with Aurobindo to support the ongoing growth plans of these businesses. [15]

In May 2024, TheraNym Biologics, a wholly-owned subsidary of Aurobindo Pharma Ltd signed a pact with Merck & Co. for expanding its biologics manufacturing facilities and exploring contract manufacturing operations for biologics. [16]

In December 2016, 20 American attorneys general filed a civil complaint accusing Aurobindo Pharma of a coordinated scheme to artificially maintain high prices for a generic antibiotic and diabetes drug. The complaint alleged price collusion schemes between six pharmaceutical firms including informal gatherings, telephone calls, and text messages. [17]

On 11 April 2018, Aurobindo was featured in the Dutch documentary television program Zembla . [18] It details accusations against the company of both environmental damage and poor working conditions for their employees in Hyderabad, India.

On 20 June 2019, Aurobindo received a warning letter from the USFDA after an inspection of its drug manufacturing facility, Aurobindo Pharma Limited in Pydibhimavaram, Srikakulam District, Andhra Pradesh. [19] The warning letter summarized significant deviations from current good manufacturing practices (cGMP) for active pharmaceutical ingredients (API).

On 7 October 2019, Aurobindo said it received seven observations from the USFDA for its unit-7 formulation plant in Telangana, with regard to potentially misleading documentation. [20] This caused its share prices to drop over 20%. [21]

Recalls

In 2018, [22] and 2019, [23] Aurobindo Pharma USA recalled tablets containing valsartan due to the detection of N-Nitrosodiethylamine (NDEA) which is a probable human carcinogen.

In November 2019, Aurobindo Pharma USA recalled ranitidine tablets, capsules, and syrup due to the detection of unacceptable levels of N-nitrosodimethylamine (NDMA). [24]

See also

Related Research Articles

<span class="mw-page-title-main">Over-the-counter drug</span> Medication available without a prescription

Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a requirement for a prescription from a healthcare professional, as opposed to prescription drugs, which may be supplied only to consumers possessing a valid prescription. In many countries, OTC drugs are selected by a regulatory agency to ensure that they contain ingredients that are safe and effective when used without a physician's care. OTC drugs are usually regulated according to their active pharmaceutical ingredient (API) and strengths of final products.

<span class="mw-page-title-main">Metformin</span> Medication used to treat diabetes by reducing glucose levels

Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. It is sometimes used as an off-label adjunct to lessen the risk of metabolic syndrome in people who take antipsychotics. Metformin is not associated with weight gain and is taken by mouth.

Ranbaxy Laboratories Limited was an Indian multinational pharmaceutical company that was incorporated in India in 1961 and remained an entity until 2014. The company went public in 1973. Ownership of Ranbaxy changed twice over the course of its history.

<span class="mw-page-title-main">Angiotensin II receptor blocker</span> Group of pharmaceuticals that modulate the renin–angiotensin system

Angiotensin II receptor blockers (ARBs), formally angiotensin II receptor type 1 (AT1) antagonists, also known as angiotensin receptor blockers, angiotensin II receptor antagonists, or AT1 receptor antagonists, are a group of pharmaceuticals that bind to and inhibit the angiotensin II receptor type 1 (AT1) and thereby block the arteriolar contraction and sodium retention effects of renin–angiotensin system.

<span class="mw-page-title-main">Ranitidine</span> Medication that decreases stomach acid

Ranitidine, previously sold under the brand name Zantac among others, is a medication used to decrease stomach acid production. It was commonly used in treatment of peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. It can be given by mouth, injection into a muscle, or injection into a vein.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

<span class="mw-page-title-main">Losartan</span> Blood pressure medication

Losartan, sold under the brand name Cozaar among others, is a medication used to treat high blood pressure (hypertension). It is in the angiotensin receptor blocker (ARB) family of medication, and is considered protective of the kidneys. Besides hypertension, it is also used in diabetic kidney disease, heart failure, and left ventricular enlargement. It comes as a tablet that is taken by mouth. It may be used alone or in addition to other blood pressure medication. Up to six weeks may be required for the full effects to occur.

<span class="mw-page-title-main">Valsartan</span> Angiotensin II receptor antagonist

Valsartan, sold under the brand name Diovan among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. It belongs to a class of medications referred to as angiotensin II receptor blockers (ARBs). It is a reasonable initial treatment for high blood pressure. It is taken by mouth.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

Torrent Pharmaceuticals Ltd is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.

<span class="mw-page-title-main">Zydus Lifesciences</span> Indian multinational pharmaceutical company

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad, which is primarily engaged in the manufacturing of generic drugs. The company ranked 100th in the Fortune India 500 list in 2020.

<i>N</i>-Nitrosodimethylamine Chemical compound

N-Nitrosodimethylamine (NDMA), also known as dimethylnitrosamine (DMN), is an organic compound with the formula (CH3)2NNO. It is one of the simplest members of a large class of nitrosamines. It is a volatile yellow oil. NDMA has attracted wide attention as being highly hepatotoxic and a known carcinogen in laboratory animals.

<i>N</i>-Nitrosodiethylamine Chemical compound

N-Nitrosodiethylamine (NDEA) is an organic compound with the formula Et2NNO (Et = C2H5). A member of the nitrosamines, it is a light-sensitive, volatile, clear yellow oil that is soluble in water, lipids, and other organic solvents. It has an amine or aromatic odor. It is used as gasoline and lubricant additive, antioxidant, and stabilizer for industry materials. When heated to decomposition, N-nitrosodiethylamine emits toxic fumes of nitrogen oxides. N-Nitrosodiethylamine affects DNA integrity, probably by alkylation, and is used in experimental research to induce liver tumorigenesis. It is carcinogenic and mutagenic. NDEA has also been found to perturb amino acid biosynthesis including arginine, as well as DNA damage repair and mitochondrial genome maintenance in yeast.

Unichem Laboratories is an Indian pharmaceutical company, headquartered in Mumbai. It manufactures and markets pharmaceutical formulations across the globe, including the regulated markets of the USA and Europe.

<span class="mw-page-title-main">Hydrocodone/ibuprofen</span> Combination drug

Hydrocodone/ibuprofen (INNs), sold under the brand name Vicoprofen, is a fixed-dose combination analgesic medication used in short-term therapy to relieve severe pain. Vicoprofen combines the analgesic and antitussive properties of hydrocodone with the analgesic, anti-inflammatory, and antipyretic properties of ibuprofen. In contrast to hydrocodone/acetaminophen combination analgesics such as Vicodin, this hydrocodone/ibuprofen avoids some of the liver toxicity which may occur from acetaminophen, but still presents significant dangers in hydrocodone overdose, namely respiratory depression. Vicoprofen is supplied in a fixed dose combination tablet which contains hydrocodone bitartrate, USP 7.5 mg with ibuprofen, USP 200 mg. Additional strengths of generic Vicoprofen are now available, in combinations of 5 mg/200 mg and 10 mg/200 mg respectively.

Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Pune. Emcure's product portfolio includes tablets, capsules and injectables. The company is a major producer of HIV antivirals, as well as gynaecology and blood therapeutic drugs.

<span class="mw-page-title-main">Taro Pharmaceuticals</span> Generic pharmaceutical company

Taro Pharmaceutical Industries is an Israeli research-based pharmaceutical manufacturer publicly listed in the New York Stock Exchange. The company has more than 180 of its own drugs sold all over the world, reaching the markets of over 25 countries. The company's products are mainly sold in the United States, Canada and Israel. Taro Pharmaceutical Industries is reported to be on steady growth since 2008.

References

  1. 1 2 "Aurobindo Overview".
  2. ↑ "Aurobindo Pharma Limited Annual Report 2019-20" (PDF). Archived from the original (PDF) on 13 August 2020.
  3. 1 2 3 "Earnings Presentation-Q4 FY 2023-24" (PDF). Aurobondo Pharma. Retrieved 29 May 2024.
  4. 1 2 "Aurobindo Pharma Ltd. Financial Statements". moneycontrol.com.
  5. ↑ "Aurobindo Pharma Limited Annual Report 2016-17" (PDF). Archived from the original (PDF) on 21 January 2022.
  6. 1 2 3 "Aurobindo Pharma Ltd: Company Overview, History, Contacts | Brand India Pharma". www.brandindiapharma.in. Retrieved 15 October 2019.
  7. ↑ "Aurobindo Pharma signs supply pact with AstraZeneca", The Economic Times, 6 September 2010
  8. ↑ "Pfizer, Astra deals to drive Aurobindo Pharma’s growth", The Economic Times, 5 November 2010
  9. ↑ "Know 10 largest Pharmaceutical Companies in India". Edu Dwar. 12 January 2023. Retrieved 28 July 2023.
  10. ↑ "Aurobindo Buys Actavis' European Operations". News: Industry Watch. Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. 15 February 2014. p. 10.
  11. ↑ "Aurobindo To Buyout Actavis' EU Ops". Bloomberg TV India. Retrieved 20 January 2014.
  12. ↑ Sridhar, G Naga (12 January 2018). "Aurobindo Pharma to focus on high-value products in US". Business Line. Retrieved 6 January 2019.
  13. ↑ PTI (7 January 2017). "Aurobindo Pharma to acquire Portugal's Generis for €135 million". mint. Retrieved 12 April 2021.
  14. ↑ Trivedi, Isha (10 February 2017). "Aurobindo Pharma buys 4 biosimilar products from TL Biopharmaceutical". mint. Retrieved 12 April 2021.
  15. ↑ Limited, Aurobindo Pharma. "Aurobindo Signs a Definitive Agreement to Acquire Apotex' Businesses in Poland, Czech Republic, the Netherlands, Spain and Belgium". PR Newswire. Retrieved 12 April 2021.
  16. ↑ "Aurobindo arm TheraNym inks pact with MSD for biologics manufacturing". Business Standard. Retrieved 1 June 2024.
  17. ↑ Thomas, Katie (15 December 2016). "20 States Accuse Generic Drug Companies of Price Fixing". The New York Times . Retrieved 16 December 2016.
  18. ↑ "'Manufacturer of Dutch medicines exploit workers and pollute the environment' - Zembla - BNNVARA". Zembla (in Dutch). Retrieved 12 April 2021.
  19. ↑ Research, Center for Drug Evaluation and (2 July 2019). "Aurobindo Pharma Limited - 577033 - 06/20/2019". Center for Drug Evaluation and Research. Retrieved 12 April 2021.
  20. ↑ "Documents potentially misleading in Aurobindo Pharma's Unit-VII: USFDA". The Economic Times. 10 October 2019. Retrieved 15 October 2019.
  21. ↑ "Aurobindo Pharma share crashes 20% to hit 52-week low on USFDA observations; Lupin, Glenmark fall up to 9%". businesstoday.in. 7 October 2019. Retrieved 15 October 2019.
  22. ↑ "Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 80 Lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP, Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity". Food and Drug Administration . 31 December 2018. Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  23. ↑ "AurobindoPharma USA, Inc. Initiates a Voluntary Nationwide Consumer Level Recall Expansion of 38 Lots of Amlodipine Valsartan Tablets USP and Valsartan Tablets, USP due to the detection of NDEA (N-Nitrosodiethylamine) Impurity". Food and Drug Administration . 1 March 2019. AurobindoPharma USA, Inc. and Acetris Health LLC. Are conducting a voluntary recall expansion of 39 lots of Valsartan and Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. This recall is an expansion of the recall initiated 12/31/18 The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  24. ↑ "Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 38 Lots of Ranitidine Tablets 150mg, Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL Due to the Detection of NDMA (Nitrosodimethylamine) Impurity". U.S. Food and Drug Administration (FDA). 6 November 2019. Archived from the original on 11 November 2019. Retrieved 10 November 2019. Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 1 lot of Ranitidine Tablets 150mg to the retail level and 37 lots of Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL to the consumer level due to the detection of NDMA (Nitrosodimethylamine) Impurity in the finished product. The impurity detected is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.PD-icon.svg This article incorporates text from this source, which is in the public domain .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.